Targeting immune vulnerabilities in small cell lung cancer
Official title: Targeting the immunologic vulnerabilities of small cell lung carcinoma
Funded at University of Michigan at Ann Arbor · NIH-11384862 · Data updated 2026-11-12
A physician-scientist is undergoing a five-year training program to understand how immune cells interact with small cell lung cancer and to build skills for a future independent lab career.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | September 1, 2022 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $207,930 |
| NIH project number | 5K08CA270077-06 |
| Project ID | NIH-11384862 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with small cell lung cancer or related tumor types may benefit from future translational applications stemming from this work.
✕Less likely to help
Initial training outcomes may not immediately improve patient care for all participants during the mentored period.
What this research studies
This NIH K08 grant supports a career development path focused on tumor immunobiology and how tumors’ immune environment is shaped. The trainee will gain expertise in antigen discovery, high-resolution expression profiling, and cell-intrinsic and -extrinsic immune regulatory mechanisms within the tumor microenvironment. The program combines hands-on lab work with clinical service in diagnostic molecular pathology, guided by an experienced mentor and an advisory committee. The goal is to become an independent researcher who can translate immunology insights into new approaches for treating small cell lung cancer.
Why it matters
Potential benefit: If successful, the research could lead to new immune-targeted therapies or biomarkers for small cell lung cancer.
How similar studies have gone: There is a translational track record in tumor immunology showing promise for immunotherapy in lung cancers, though direct applications to small cell lung cancer remain under development.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Mahadevan, Navin — University of Michigan at Ann Arbor
- Study coordinator: Mahadevan, Navin
Related research
Other NIH-funded projects on the same topics.
-
Investigating immune weaknesses in small cell lung cancer
This study is looking at how the immune system works with small cell lung cancer to find new ways to help it fight the disease, and it's designed for patients who want to learn more about potential treatments.
-
How small cell lung cancer cells switch between different states
This research looks at how cells inside small cell lung cancer change into different types and how those changes affect treatment for people with SCLC.
-
Understanding how small cell lung cancer adapts and resists treatment
This study is looking at small cell lung cancer to understand why it grows so quickly and resists treatment, using special models from patients to find new ways to improve care for people facing this tough disease.
-
A new treatment for squamous cell lung cancer using targeted therapy
This study is testing a new treatment for squamous cell lung cancer that uses a special drug designed to deliver chemotherapy directly to cancer cells, which could help patients feel better and live longer while protecting healthy tissues.
-
Combining targeted therapies to treat difficult lung cancer cases
This study is testing a new way to treat advanced non-small cell lung cancer by using a special self-injectable medicine that targets specific proteins causing the cancer, with the hope of making treatments work better for patients.
-
Novel idea: Epstein-Barr virus and eye cancer in people living with HIV in Zimbabwe
A study explores whether Epstein-Barr virus could cause a type of eye cancer in people living with HIV in Zimbabwe.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.